Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
L274683-1mg | 1mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $76.90 | |
L274683-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $91.90 | |
L274683-10mg | 10mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $166.90 |
Selective group III mGlu agonist
Synonyms | L-APB | 1-(2,5 DIMETHOXYPHENYL)-2-AMINOETHANOL | 3-METHOXY-PIPERIDINEHYDROCHLORIDE | GTPL1410 | BDBM50007548 | CHEBI:143992 | CS-0020419 | L-1-amino-4-phosphonobutanoic acid | L-2-amino-4-phosphonobutiric acid | NCGC00024468-02 | AKNQMEBLVAMSNZ-UHFFFAOYSA |
---|---|
Specifications & Purity | Moligand™, ≥99% |
Biochemical and Physiological Mechanisms | Selective group III mGlu receptor agonist. Also available in simple stock solutions - add 1 ml of water to get an exact, ready-to-use concentration.MGluR4 and mGluR6 metabotropic glutamate receptor agonists. |
Storage Temp | Protected from light,Store at -20°C,Desiccated |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | AGONIST |
Mechanism of action | Agonist of mGlu 4 receptor;Agonist of mGlu 8 receptor |
Note | Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | Store at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | (2S)-2-amino-4-phosphonobutanoic acid |
---|---|
INCHI | InChI=1S/C4H10NO5P/c5-3(4(6)7)1-2-11(8,9)10/h3H,1-2,5H2,(H,6,7)(H2,8,9,10)/t3-/m0/s1 |
InChi Key | DDOQBQRIEWHWBT-VKHMYHEASA-N |
Canonical SMILES | C(CP(=O)(O)O)C(C(=O)O)N |
Isomeric SMILES | C(CP(=O)(O)O)[C@@H](C(=O)O)N |
Alternate CAS | 23052-81-5 |
PubChem CID | 179394 |
MeSH Entry Terms | 2-amino-4-phosphono-propinate;L-AP4 |
Molecular Weight | 183.1 |
Enter Lot Number to search for COA:
Solubility | Soluble in water to 100 mM;Soluble to 5 mM in water and to 100 mM in 1eq. NaOH |
---|---|
Sensitivity | Light sensitive |
Pictogram(s) | GHS07 |
---|---|
Signal | Warning |
Hazard Statements | H315:Causes skin irritation H319:Causes serious eye irritation H335:May cause respiratory irritation |
Precautionary Statements | P261:Avoid breathing dust/fume/gas/mist/vapors/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P271:Use only outdoors or in a well-ventilated area. P304+P340:IF INHALED: Remove person to fresh air and keep comfortable for breathing. P403+P233:Store in a well-ventilated place. Keep container tightly closed. P362+P364:Take off contaminated clothing and wash it before reuse. P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes. P337+P317:If eye irritation persists: Get medical help. P332+P317:If skin irritation occurs: Get medical help. P319:Get medical help if you feel unwell. |
1. Goudet C, Vilar B, Courtiol T, Deltheil T, Bessiron T, Brabet I, Oueslati N, Rigault D, Bertrand HO, McLean H et al.. (2012) A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential.. FASEB J, 26 (4): (1682-93). [PMID:22223752] [10.1021/op500134e] |
2. Kalinichev M, Rouillier M, Girard F, Royer-Urios I, Bournique B, Finn T, Charvin D, Campo B, Le Poul E, Mutel V et al.. (2013) ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization.. J Pharmacol Exp Ther, 344 (3): (624-36). [PMID:23257312] [10.1021/op500134e] |
3. Pittolo S, Gómez-Santacana X, Eckelt K, Rovira X, Dalton J, Goudet C, Pin JP, Llobet A, Giraldo J, Llebaria A et al.. (2014) An allosteric modulator to control endogenous G protein-coupled receptors with light.. Nat Chem Biol, 10 (10): (813-5). [PMID:25173999] [10.1021/op500134e] |
4. Niswender CM, Johnson KA, Miller NR, Ayala JE, Luo Q, Williams R, Saleh S, Orton D, Weaver CD, Conn PJ. (2010) Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7.. Mol Pharmacol, 77 (3): (459-68). [PMID:20026717] [10.1021/op500134e] |
5. Niswender CM, Johnson KA, Weaver CD, Jones CK, Xiang Z, Luo Q, Rodriguez AL, Marlo JE, de Paulis T, Thompson AD et al.. (2008) Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4.. Mol Pharmacol, 74 (5): (1345-58). [PMID:18664603] [10.1021/op500134e] |
6. Yin S, Noetzel MJ, Johnson KA, Zamorano R, Jalan-Sakrikar N, Gregory KJ, Conn PJ, Niswender CM. (2014) Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS.. J Neurosci, 34 (1): (79-94). [PMID:24381270] [10.1021/op500134e] |
7. Klyuch BP et al.. (2012) Deletion of ecto-5'-nucleotidase (CD73) reveals direct action potential-dependent adenosine release.. J Neurosci, 32 (11): (3842-7). [PMID:22423104] |
8. Lopez S et al.. (2007) Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease.. J Neurosci, 27 (25): (6701-11). [PMID:17581957] |
9. Atterbury A & Wall MJ. (2011) A population of immature cerebellar parallel fibre synapses are insensitive to adenosine but are inhibited by hypoxia.. Neuropharmacology, 61 (4): (880-8). [PMID:21693125] |
10. Selvam C et al.. (2010) A virtual screening hit reveals new possibilities for developing group III metabotropic glutamate receptor agonists.. J Med Chem, 53 (7): (2797-813). [PMID:20218620] |
11. Vilar B et al.. (2013) Alleviating pain hypersensitivity through activation of type 4 metabotropic glutamate receptor.. J Neurosci, 33 (48): (18951-65). [PMID:24285900] |
12. Špirková A et al.. (2022) Glutamate can act as a signaling molecule in mouse preimplantation embryos†.. Biol Reprod, 107 (4): (916-927). [PMID:35746896] |
13. Ayala JE et al.. (2008) Group III mGluR regulation of synaptic transmission at the SC-CA1 synapse is developmentally regulated.. Neuropharmacology, 54 (5): (804-14). [PMID:18255102] |
14. Buldyrev I & Taylor WR. (2013) Inhibitory mechanisms that generate centre and surround properties in ON and OFF brisk-sustained ganglion cells in the rabbit retina.. J Physiol, 591 (Pt 1): (303-25). [PMID:23045347] |
15. Huang S et al.. (2011) Interdomain movements in metabotropic glutamate receptor activation.. Proc Natl Acad Sci U S A, 108 (37): (15480-5). [PMID:21896740] |
16. Errington AC et al.. (2011) mGluR control of interneuron output regulates feedforward tonic GABAA inhibition in the visual thalamus.. J Neurosci, 31 (23): (8669-80). [PMID:21653871] |
17. Gosnell HB et al.. (2011) mGluR8 modulates excitatory transmission in the bed nucleus of the stria terminalis in a stress-dependent manner.. Neuropsychopharmacology, 36 (8): (1599-607). [PMID:21451497] |
18. Ribeiro J et al.. (2021) Restoration of visual function in advanced disease after transplantation of purified human pluripotent stem cell-derived cone photoreceptors.. Cell Rep, 35 (3): (109022). [PMID:33882303] |
19. Pérez-Fernández V et al.. (2019) Rod Photoreceptor Activation Alone Defines the Release of Dopamine in the Retina.. Curr Biol, 29 (5): (763-774.e5). [PMID:30799247] |
20. Tikidji-Hamburyan A et al.. (2017) Rods progressively escape saturation to drive visual responses in daylight conditions.. Nat Commun, 8 (1813). [PMID:29180667] |
21. Reinhard K et al.. (2014) Step-by-step instructions for retina recordings with perforated multi electrode arrays.. PLoS One, 9 (8): (e106148). [PMID:25165854] |